Un catálogo de las evaluaciones británicas de medicamentos accesibles por Internet
El Specialist Pharmacy Service británico actualiza regularmente la lista de las evaluaciones de medicamentos disponibles libremente a través de Internet. Specialist Pharmacy Service , 4 de diciembre de 2017
Specialist Pharmacy Service , 4 de diciembre de 2017
El Specialist Pharmacy Service británico actualiza regularmente la lista de las evaluaciones de medicamentos disponibles libremente a través de Internet. Los organismos productores de las evaluaciones catalogadas incluyen:
- AWMSG – All Wales Medicines Strategy Group
- LMEN – London Medicines Evaluation Network
- MTRAC – Midland Therapeutic Review & Advisory Committee
- NTAG – Northern Treatment Advisory Group
- NICE – National Institute for Health and Care Excellence
- NICE-ES – NICE Evidence Summary
- NIHR – National Institute for Health Research
- RDTC – Regional Drug & Therapeutics Centre
- SMC – Scottish Medicines Consortium
- UKMi – United Kingdom Medicines Information
La lista completa se descarga como archivo Excel aquí.
Para acceder a las evaluaciones, localice en la tabla el medicamento y la indicación de interés y siga el enlace de la columna de la derecha. A continuación se listan los documentos incorporados en el último mes:
|
Nombre del fármaco |
Indicación |
Fuente |
|
Abatacept (Orencia) |
Active psoriatic arthritis in adult patients with an inadequate response to previous DMARD therapy including methotrexate, and for whom additional systemic therapy for psoriatic skin lesions is not required – monotherapy or in combination with methotrexate |
|
|
Aflibercept |
Choroidal neovascularisation |
|
|
Ceftazidime + avibactam (Zavicefta) |
Complicated intra-abdominal infection, complicated urinary tract infection including pyelonephritis, hospital-acquired pneumonia including ventilator associated pneumonia and treatment of aerobic Gram-negative organisms in adult patients with limited treatment options |
|
|
Everolimus (Certican) |
Prophylaxis of organ rejection in adult patients at low-to-moderate immunological risk receiving an allogenic renal transplant |
|
|
Glecaprevir + pibrentasvir (Maviret) |
Chronic hepatitis C infection in adults |
|
|
Ibrutinib |
Waldenström’s macroglobulinaemia |
|
|
Ibrutinib |
Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation |
|
|
Liraglutide (Saxenda) |
Obesity (update) |
|
|
Mercaptamine (Procysbi) |
Proven nephropathic cystinosis |
|
|
Midazolam (Epistatus) |
Prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years |
|
|
Naltrexone + bupropion (Mysimba) |
Weight management in adults (update) |
|
|
Nivolumab |
Squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
|
|
Nivolumab |
Relapsed or refractory classical Hodgkin lymphoma (update) |
|
|
Nivolumab |
Previously treated advanced renal cell carcinoma (update) |
|
|
Nivolumab |
Previously treated non-squamous non-small-cell lung cancer |
|
|
Nivolumab |
Previously treated squamous non-small-cell lung cancer |
|
|
Olaratumab |
Advanced soft tissue sarcoma – in combination with doxorubicin |
|
|
Pegvisomant (Somavert) |
Acromegaly in adults who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-1 concentrations or was not tolerated |
|
|
Pegvisomant (Somavert) |
Acromegaly in adults who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-1 concentrations or was not tolerated |
|
|
Raltegravir 600mg film-coated tablets |
HIV-1 infection in adults and paediatric patients weighing at least 40 kg – in combination with other anti-retrovirals |
|
|
Regorafenib |
Previously treated unresectable or metastatic gastrointestinal stromal tumours |
|
|
Ritiximab biosimilars (Truxima, Rixathon) |
Non-Hodgkins lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis |
|
|
Sarilumab |
Moderate-to-severe active rheumatoid arthritis |
|
|
Stiripentol (Diacomit) |
Refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) – in conjunction with clobazam and valproate |
|
|
Venetoclax |
Chronic lymphocytic leukaemia |
|
|
Vismodegib |
Basal cell carcinoma |
La fuente original:
New product evaluations – a resource for medicines management (November 2017). Specialist Pharmacy Service [Internet], 4 de diciembre de 2017.
Disponible en: http://bit.ly/2nx8y6v